BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 62 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2013. The put-call ratio across all filers is 3.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,693,666 | +362.6% | 1,086,676 | +360.0% | 0.00% | +200.0% |
| Q2 2023 | $1,662,989 | -15.6% | 236,220 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,970,075 | -27.4% | 236,220 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $2,711,806 | -8.7% | 236,220 | +0.2% | 0.00% | 0.0% |
| Q3 2022 | $2,970,000 | +19.1% | 235,720 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,494,000 | -24.3% | 235,720 | +16.3% | 0.00% | 0.0% |
| Q1 2022 | $3,295,000 | +1.7% | 202,620 | -13.4% | 0.00% | 0.0% |
| Q4 2021 | $3,240,000 | -3.6% | 233,920 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $3,361,000 | -10.4% | 233,920 | -1.4% | 0.00% | -50.0% |
| Q2 2021 | $3,752,000 | +81.5% | 237,320 | +16.8% | 0.00% | +100.0% |
| Q1 2021 | $2,067,000 | +55.2% | 203,220 | +13.6% | 0.00% | 0.0% |
| Q4 2020 | $1,332,000 | +116.9% | 178,820 | 0.0% | 0.00% | – |
| Q3 2020 | $614,000 | -31.7% | 178,820 | -5.2% | 0.00% | -100.0% |
| Q2 2020 | $899,000 | +86.1% | 188,720 | -21.8% | 0.00% | – |
| Q1 2020 | $483,000 | -8.9% | 241,320 | +57.0% | 0.00% | – |
| Q4 2019 | $530,000 | +20.5% | 153,720 | 0.0% | 0.00% | – |
| Q3 2019 | $440,000 | -17.6% | 153,720 | +9.0% | 0.00% | – |
| Q2 2019 | $534,000 | -43.6% | 141,020 | +21.2% | 0.00% | -100.0% |
| Q1 2019 | $947,000 | +0.9% | 116,320 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $939,000 | +5.7% | 116,320 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $888,000 | +33.1% | 116,320 | 0.0% | 0.00% | – |
| Q2 2018 | $667,000 | +20.2% | 116,320 | 0.0% | 0.00% | – |
| Q1 2018 | $555,000 | +13.7% | 116,320 | +17.0% | 0.00% | – |
| Q4 2017 | $488,000 | -6.3% | 99,420 | 0.0% | 0.00% | – |
| Q3 2017 | $521,000 | -12.9% | 99,420 | -7.6% | 0.00% | – |
| Q2 2017 | $598,000 | -33.8% | 107,620 | 0.0% | 0.00% | -100.0% |
| Q1 2017 | $904,000 | +18.8% | 107,620 | -10.5% | 0.00% | 0.0% |
| Q4 2016 | $761,000 | +36.6% | 120,220 | -4.8% | 0.00% | – |
| Q3 2016 | $557,000 | +44.3% | 126,220 | -7.2% | 0.00% | – |
| Q2 2016 | $386,000 | +15.2% | 136,020 | +14.9% | 0.00% | – |
| Q1 2016 | $335,000 | -72.7% | 118,420 | -0.4% | 0.00% | -100.0% |
| Q4 2015 | $1,228,000 | -9.0% | 118,950 | +0.4% | 0.00% | 0.0% |
| Q3 2015 | $1,350,000 | -23.8% | 118,420 | -0.2% | 0.00% | 0.0% |
| Q2 2015 | $1,771,000 | +82.0% | 118,600 | +10.0% | 0.00% | 0.0% |
| Q1 2015 | $973,000 | -25.8% | 107,800 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,311,000 | +24.4% | 107,800 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $1,054,000 | -21.9% | 107,800 | +1.9% | 0.00% | 0.0% |
| Q2 2014 | $1,349,000 | +9535.7% | 105,800 | +1058.1% | 0.00% | – |
| Q2 2013 | $14,000 | – | 9,136 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |